See more : Coplus Inc. (2254.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Praxis Precision Medicines, Inc. (PRAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Praxis Precision Medicines, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Genii Ideas Co., Ltd. (7631.TWO) Income Statement Analysis – Financial Results
- Technoprobe S.p.A. (TPRO.MI) Income Statement Analysis – Financial Results
- D’Ieteren Group SA (SIEVF) Income Statement Analysis – Financial Results
- Giglio Group S.p.A. (GG.MI) Income Statement Analysis – Financial Results
- Sagaliam Acquisition Corp. (SAGAR) Income Statement Analysis – Financial Results
Praxis Precision Medicines, Inc. (PRAX)
About Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.45M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.17M | 1.59M | 746.00K | 679.00K | 1.00K |
| Gross Profit | 2.45M | -1.17M | -1.59M | -746.00K | -679.00K | -1.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 86.77M | 155.04M | 120.26M | 44.98M | 29.56M | 18.82M |
| General & Administrative | 42.05M | 59.95M | 47.08M | 16.99M | 6.23M | 3.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 42.05M | 59.95M | 47.08M | 16.99M | 6.23M | 3.90M |
| Other Expenses | 0.00 | 957.00K | 271.00K | 140.00K | 0.00 | -3.65M |
| Operating Expenses | 128.82M | 214.99M | 167.33M | 61.97M | 35.79M | 22.72M |
| Cost & Expenses | 128.82M | 214.99M | 167.33M | 61.97M | 35.79M | 22.72M |
| Interest Income | 3.10M | 0.00 | 271.00K | 140.00K | 193.00K | 92.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 127.00K |
| Depreciation & Amortization | 432.00K | 1.17M | 1.59M | 746.00K | 679.00K | 1.00K |
| EBITDA | -125.94M | -212.86M | -165.47M | -61.08M | -34.92M | -26.27M |
| EBITDA Ratio | -5,146.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -126.37M | -214.99M | -167.33M | -61.97M | -35.79M | -22.72M |
| Operating Income Ratio | -5,164.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.10M | 957.00K | 271.00K | 140.00K | 193.00K | -3.68M |
| Income Before Tax | -123.28M | -214.03M | -167.06M | -61.83M | -35.60M | -26.40M |
| Income Before Tax Ratio | -5,037.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -957.00K | -182.00K | -8.00K | -84.00K | 133.00K |
| Net Income | -123.28M | -213.07M | -166.88M | -61.82M | -35.51M | -26.54M |
| Net Income Ratio | -5,037.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| EPS Diluted | -18.69 | -69.33 | -58.96 | -103.61 | -348.24 | -306.73 |
| Weighted Avg Shares Out | 6.59M | 3.07M | 2.83M | 596.68K | 101.98K | 86.51K |
| Weighted Avg Shares Out (Dil) | 6.59M | 3.07M | 2.83M | 596.68K | 101.98K | 86.51K |
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?
Praxis Precision Medicines, Inc. (PRAX) Q2 2024 Earnings and Corporate Update Call Transcript
Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
Source: https://incomestatements.info
Category: Stock Reports